Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$4.64
$0.15(3.87%)
At close: 4:00 PM EDT
$4.64
$0.15(3.87%)
Day’s Range― - ―
52-Week Range$2.62 - $15.70
Previous Close$4.04
Volume3.69M
Average Volume (3M)4.17M
Market Cap
$390.16M
Enterprise Value$743.22M
Total Cash (Recent Filing)$218.01M
Total Debt (Recent Filing)$371.93M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Jan 11, 2027EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding147,787,520
10 Day Avg. Volume3,878,968
30 Day Avg. Volume4,171,422
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market Cap1.90
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit2.71
Enterprise Value/Ebitda-40.12
Forecast
1Y Price Target
$6.19Price Target Upside33.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
Diversified Global PlatformThe broad mix of cannabis, beverages, wellness, and pharmaceutical distribution reduces reliance on any single category or geography. Its presence in more than 25 countries also creates multiple avenues for expansion and allows stronger businesses to offset weaker segments over time.
Beverage Growth And ProfitabilityRapid beverage growth, improving gross margin, and BrewDog reaching profitability indicate that operational restructuring is translating into stronger segment economics. A healthier beverage platform can provide recurring cash contribution and diversify Tilray beyond regulated cannabis markets.
International Cannabis CapabilitiesGrowing international medical cannabis demand, expanding EU-GMP shipments, and established operations in Europe support a durable position in regulated markets. This infrastructure may help Tilray capture patient growth while benefiting from higher-return product and geographic mix.
Bears Say
Persistent Losses And Cash BurnNegative operating and free cash flow show that the business is not yet self-funding, despite some improvement from prior periods. Continued cash burn can constrain investment, increase reliance on financing actions, and make sustainable profitability more difficult to achieve.
Cannabis Revenue And Pricing PressureDeclining cannabis revenue and international price compression weaken the economics of a core operating segment. Even with better gross margins, lower absolute gross profit can limit the segment's contribution and make future growth dependent on mix, volume, and cost improvements.
Capital Structure And Maturity PressureOngoing interest expense reduces the cash available for operations while the approaching maturity requires further refinancing or balance-sheet actions. Debt-for-equity exchanges can improve flexibility, but they also demonstrate continuing capital structure pressure and dilute existing shareholders.
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $2.62 and its highest was $15.70 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $390.16M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jan 11, 2027 which is in 72 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Oct 08, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.181 by -$0.139.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.16.
How many shares outstanding does Tilray have?
Tilray has 147,787,520 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.181. Following the earnings report the stock price went down -3.365%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.19 (33.51% Upside)
$6.19 (33.51% Upside)
Blogger Sentiment
Bullish
TLRY Sentiment 62%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $69.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.58%
12-Months-Change
Fundamentals
Return on Equity
-9.38%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Tilray reported record revenue and gross profit, expanding consolidated and cannabis margins, strong international cannabis and BrewDog growth, U.S. craft beer brand momentum, debt reduction, and reaffirmed fiscal 2027 adjusted EBITDA guidance. These strengths were partly offset by a $40 million net loss, lower adjusted EBITDA, total cannabis revenue contraction, international price compression, Canadian adult-use headwinds, fuel costs, higher investment costs, and continued regulatory and market uncertainty.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$6.19
▲(33.51% Upside)
Technical Analysis
Ownership Overview
2.02% Insiders
0.31% Mutual Funds
0.13% Other Institutional Investors
94.28% Public Companies and
Individual Investors












